contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


comment-from-karo-pharma-aktiebolags-board-of-directors-regarding-the-public-offer-from-karo-intressenter-ab

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Karo Pharma verkar inom vardagshälsa. Bolaget äger och kommersialiserar receptbelagda läkemedel och receptfria konsumentprodukter som säljs i apotek och detaljhandel samt via online-kanaler. Genom direkta försäljningsorganisationer och distributörsnätverk är bolagets produkter tillgängliga globalt, men med dess kärnverksamhet i Europa. Bolaget har sitt huvudkontor i Stockholm.



Karo Pharma

Today, on 16 August 2022, Karo Intressenter AB[1] ("Karo Intressenter") announced a public cash offer to the shareholders in Karo Pharma Aktiebolag ("Karo Pharma") to acquire the shares in Karo...

<div class="abstract">Today, on 16 August 2022, Karo Intressenter AB[1] ("Karo Intressenter") announced a public cash offer to the shareholders in Karo Pharma Aktiebolag ("Karo Pharma") to acquire the shares in Karo Pharma not already held by Karo Intressenter at a price of SEK 60 per share (the "Offer").</div>For further information about the Offer, please refer to Karo Intressenter's press release&nbsp;(<a href="https://news.cision.com/karo-intressenter-ab/r/karo-intressenter-ab-announces-a-public-cash-offer-to-the-shareholders-in-karo-pharma-aktiebolag,c3614453">https://news.cision.com/karo-intressenter-ab/r/karo-intressenter-ab-announces-a-public-cash-offer-to-the-shareholders-in-karo-pharma-aktiebolag,c3614453</a>). Karo Intressenter is expected to publish an offer document regarding the Offer on 17 August 2022. The acceptance period for the Offer is expected to commence on 18 August 2022 and expire on 15 September 2022.The board of directors of Karo Pharma has, in accordance with the Takeover rules for certain trading platforms, initiated the work on handling matters concerning the Offer, including to obtain a fairness opinion.Roschier Advokatbyrå AB has been appointed as legal advisor.The board of directors will revert well before and no later than two weeks prior to the expiry of the acceptance period in the Offer.Stockholm, 16 August 2022Karo Pharma AktiebolagFor additional information, please contact:Richard Edström, Head of Legal, +4670609 88 68, richard.edstrom@karopharma.comThis information is information that Karo Pharma Aktiebolag is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 16 August 2022, at 14:00 CEST.About Karo PharmaKaro Pharma offers "Smart choices for everyday healthcare". We own and commercialize reliable original brands within prescription drugs and over-the-counter consumer products. Our products are available in over 90 countries with the core in Europe and the Nordics region. The headquarter of Karo Pharma is in Stockholm and the company is listed on Nasdaq First North Growth Market.[1] A Swedish private limited liability company (Sw. privat aktiebolag) controlled by EQT VIII, registered with the Swedish Companies Registration Office (Sw. Bolagsverket) with corporate registration number 559160-9416. &nbsp;&nbsp;

Comment from Karo Pharma Aktiebolag's board of directors regarding the public offer from Karo Intressenter AB

Return on capital (ROE, ROI, ROIC, RONIC)

Drug development investment: Value creation through M&As and licensing agreements

What does negative working capital mean and why is it a good thing?

Income statement

Amazon and Costco in Sweden: A looming threat that Nordic retailers ignore at their peril

Beställ vårt nyhetsbrev — inget användarkonto krävs!